In Regents of the University of California v. Broad Institute, Inc., the Federal Circuit addressed the issue of conception and reduction to ...

Adobe is rolling out a new AI offering aiming to create common ground among major talent agencies, top filmmakers, visual effects houses and others balancing human creativity with technological ...

Explore RNA interference methods, comparing siRNA and shRNA for gene knockdown, their mechanisms, advantages, and ...

Following the historic demonstrations of September 2025, largely led by Generation Z, Madagascar has embarked on a process of ...

Genespire is looking to take its single-dose gene therapy, GENE202, to the clinic by the end of 2026, where it will be ...

We live in a moment when stories move faster than ever. Audiences discover movies, TV shows, short‑form videos, long‑form ...

BEIJING, Jan. 20, 2026 /PRNewswire/ -- Beijing Tsingke Biotech Co., Ltd., a leading biotechnology company, today announced ...

Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may ...

Explore LENN nanoparticles, a groundbreaking technology for delivering mRNA therapies to bladder cancer cells with enhanced ...

Published, peer-reviewed research shows a patent-pending, virus-mimicking platform technology developed at Purdue University ...

"High-end desktops shouldn't have to feel excessive just to be fast," said Harjit Chana, Founder at Digital Storm. "With Vector and Aventum 5, we wanted to show that you can push hardware to its ...

Inovio Pharmaceuticals faces an October 30 PDUFA date for INO-3107 with high regulatory risk and only a 5-7 month cash runway. Read why INO stock is a hold.